23:03 , Jul 18, 2019 |  BC Extra  |  Financial News

Medicxi’s new €400M fund unites early, late stage investing

Medicxi’s newly closed third fund, its largest ever, will depart from the VC’s prior strategy by consolidating early and late stage investing into a single vehicle. Medicxi III will deploy €400 million ($451.2 million) across...
16:29 , Apr 2, 2019 |  BC Extra  |  Financial News

Ocular oncology play Aura raises $40M D round

Medicxi led a $40 million series D round for Aura as the ocular oncology company prepares its lead choroidal melanoma therapy for Phase III testing in 1H20. The funding will give Aura Biosciences Inc. (Cambridge,...
23:20 , Oct 5, 2018 |  BioCentury  |  Finance

Fruitful partnerships

Arix Bioscience plc (LSE:ARIX) leveraged its partnership with Takeda Ventures to co-lead a $58 million series A round for antibody-drug company VelosBio Inc., a sign that the VC’s strategic partnerships are finally bearing fruit. Also...
00:07 , Sep 5, 2018 |  BC Extra  |  Company News

Management tracks: Agios, Radius

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said David Schenkein will step down as CEO and become executive chairman, effective Feb. 1, 2019. He will succeed Chairman John Maraganore, who is also CEO at Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)....
15:02 , Dec 22, 2017 |  BC Week In Review  |  Financial News

Aura raises $30M series C

Aura Biosciences Inc. (Cambridge, Mass.) raised $30 million in a series C round led by new investors Lundbeckfonden Ventures and Arix Bioscience plc. Existing investors also participated, including Advent Life Sciences, Chiesi Ventures, Ysios Capital,...
07:01 , Dec 21, 2017 |  BC Extra  |  Financial News

Aura raises $30M series C

Aura Biosciences Inc. (Cambridge, Mass.) raised $30 million in a series C round led by new investors Lundbeckfonden Ventures and Arix Bioscience plc. Existing investors also participated, including Advent Life Sciences, Chiesi Ventures, Ysios Capital,...
23:41 , Dec 12, 2017 |  BC Extra  |  Company News

Management tracks: Achaogen, Minerva

Antibacterial company Achaogen Inc. (NASDAQ:AKAO) said Kenneth Hillan will step down as CEO, effective Jan. 1. He will remain president and president of R&D. Blake Wise, who has served as president and COO, will become...
00:05 , May 20, 2017 |  BioCentury  |  Strategy

Henri: N of 1

Gaucher’s disease had swollen Brian Berman’s spleen to the size of a basketball and physicians at NIH told the three-year-old’s parents that it had to be removed. It was 1984, there was no effective treatment...
17:22 , May 15, 2017 |  BC Extra  |  Company News

Orphan drug giant Termeer passes away

Henri Termeer, the former chairman, president and CEO of Genzyme Corp. and one of the handful of individuals who personified the biotech industry in its early decades, passed away May 12 at age 71. Termeer...
18:57 , Apr 26, 2017 |  BC Week In Review  |  Clinical News

AU-011: Ph Ib started

Aura began an open-label, U.S. Phase Ib trial to evaluate single injections of 2 dose levels of intravitreal AU-011 in up to 12 patients. Aura Biosciences Inc. , Cambridge, Mass.  Product: AU-011   Business: Cancer ...